多发性硬化症的药物治疗进展  

Emerging therapies for multiple sclerosis

作　　者：程睿[1] 徐飞虎[1] 周胜军[1] 孙汉栋 

机构地区：[1]杭州九源基因工程有限公司,杭州310018

出　　处：《中国新药杂志》2014年第23期2748-2752,共5页Chinese Journal of New Drugs

摘　　要：多发性硬化症(MS)是一种复杂、致残的慢性神经系统疾病,全球MS患者超过210万。从1993年首个专门治疗RRMS药物获得美国FDA批准上市以来,全球已陆续批准12个疾病修饰药物(DMAs)上市。医疗专业人员需判断药物收益风险比,以确定每个患者的最佳治疗方案。本文综述了已上市的多发性硬化症的治疗药物,为临床用药提供参考。Multiple sclerosis （MS） is a complex, chronic, and often disabling neurological disease, and MS affects more than 2.1 million people worldwide. Since the first MS drug was approved by the U. S. Food and Drug Administration （FDA） specially to treat RRMS in 1993, 12 approved DMAs emerged from years in the world. Health care professionals should evaluate cost-effectiveness of the therapies to determine the treatment option that best fits the needs and preferences of individual patients.

关 键 词：多发性硬化 干扰素Β 醋酸格拉替雷 那他珠单抗 芬戈莫德 富马酸二甲酯 

分 类 号：R971[医药卫生—药品]